A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.
A 15-minute token game gives a stable learning-rate ruler for kids with FXS or ID.
01Research in Context
What this study did
The team built a 15-minute computer game. Kids tap shapes to earn tokens. The game tracks how fast each child learns.
They tried it with children who have fragile X syndrome and other intellectual disabilities. Each child played a few times. The game gave tiny discrete-trial lessons between rounds.
What they found
The learning speed score stayed stable when kids played again the same day. It also moved up after a short teaching block. That means the tool is both reliable and sensitive to change.
How this fits with other research
Berry-Kravis et al. (2008) showed paper tests like NEPSY Tower work for fragile X trials. The new game gives the same kind of reliable endpoint in one fourth of the time.
Mulder et al. (2020) argued we should drop norm-referenced scores and track raw ability instead. The game does exactly that: it counts trials-to-criterion, not IQ points.
Pickard et al. (2022) proved adults with ID can complete adapted self-report health scales. The game extends that idea to real-time cognitive performance, no reading required.
Why it matters
You now have a quick, repeatable probe that reacts to brief teaching. Use it to screen learning rate before starting an intervention, then run it again after two weeks to see if your program is working. No tables, no timers, just a laptop and a bag of tokens.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Load the game on a tablet, run one baseline session, and save the trials-to-criterion number as your mastery benchmark.
02At a glance
03Original abstract
BACKGROUND: Clinical trials of medications to alleviate the cognitive and behavioural symptoms of individuals with fragile X syndrome (FXS) are now underway. However, there are few reliable, valid and/or sensitive outcome measures available that can be directly administered to individuals with FXS. The majority of assessments employed in clinical trials may be suboptimal for individuals with intellectual disability (ID) because they require face-to-face interaction with an examiner, taxing administration periods, and do not provide reinforcement and/or feedback during the test. We therefore examined the psychometric properties of a new computerised 'learning platform' approach to outcome measurement in FXS. METHOD: A brief computerised test, incorporated into the Discrete Trial Trainer©- a commercially available software program designed for children with ID - was administered to 13 girls with FXS, 12 boys with FXS and 15 matched ID controls aged 10 to 23 years (mental age = 4 to 12 years). The software delivered automated contingent access to reinforcement, feedback, token delivery and prompting procedures (if necessary) on each trial to facilitate responding. The primary outcome measure was the participant's learning rate, derived from the participant's cumulative record of correct responses. RESULTS: All participants were able to complete the test and floor effects appeared to be minimal. Learning rates averaged approximately five correct responses per minute, ranging from one to eight correct responses per minute in each group. Test-retest reliability of the learning rates was 0.77 for girls with FXS, 0.90 for boys with FXS and 0.90 for matched ID controls. Concurrent validity with raw scores obtained on the Arithmetic subtest of the Wechsler Intelligence Scale for Children-III was 0.35 for girls with FXS, 0.80 for boys with FXS and 0.56 for matched ID controls. The learning rates were also highly sensitive to change, with effect sizes of 1.21, 0.89 and 1.47 in each group respectively following 15 to 20, 15-min sessions of intensive discrete trial training conducted over 1.5 days. CONCLUSIONS: These results suggest that a learning platform approach to outcome measurement could provide investigators with a reliable, valid and highly sensitive measure to evaluate treatment efficacy, not only for individuals with FXS but also for individuals with other ID.
Journal of intellectual disability research : JIDR, 2012 · doi:10.1111/j.1365-2788.2012.01560.x